Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 13/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190500 | 0.88 | SMN1; SMN2 (0.48) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.82 | CA12 (0.63) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL3389054 | 0.80 | CA12 (0.53) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL8737479 | 0.79 | NPC1 (0.49) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL13512752 | 0.79 | APP (0.55) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL11493726 | 0.78 | CA12 (0.51) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9429825 | 0.78 | CA12 (0.51) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL3661946 | 0.78 | GAA (0.53) | NPC1RAB9AMAPTSMN1; SMN2APP | |
| SCHEMBL11108889 | 0.77 | MAPT (0.50) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL2999592 | 0.77 | ALDH1A1 (0.55) | NPC1RAB9APOLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| CN-106458940-A | Inhibitors of human immunodeficiency virus replication | 百时美施贵宝公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| EP-3060554-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061518-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20120235148-A1 | PHOTO-CROSSLINKABLE MATERIAL FOR ORGANIC THIN FILM TRANSISTOR INSULATING LAYER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-20 | — | — | US | disclosed |
| EP-2479791-A1 | PHOTO-CROSSLINKABLE MATERIAL FOR ORGANIC THIN FILM TRANSISTOR INSULATING LAYER | Sumitomo Chemical Co., Ltd (JP) | 2012-07-25 | — | — | EP | disclosed |
| CN-102484141-A | Photo-crosslinking organic thin film transistor insulating layer material | SUMITOMO CHEMICAL CO | 2012-05-30 | — | — | CN | disclosed |
| US-20120053287-A1 | RESIN COMPOSITION FOR INSULATING LAYER | SUMITOMO CHEMICAL COMPANY, LTD (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102282186-A | Resin composition for insulating layer | — | 2011-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR1E, POLR1G | NPC1 260/4885RAB9A 2160/4885POLB 15/4885 |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR1G, POLR1E | NPC1 290/4885RAB9A 2217/4885POLB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.